Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientif...(al biologic and small molecule medicines...),Health

Date:10/16/2009

al biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com

Wyeth is now a wholly owned subsidiary of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory obligations.

More information is available at www.pfizer.com.

Follow Pfizer on www.Twitter.com/pfizer_news.

Amgen Forward-Looking Statement

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and unc
'/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
2. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 27
3. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 26
4. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25
5. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24
6. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
7. PolyOne Presented with Frost & Sullivan Medical Product Award
8. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
9. Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
10. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
11. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco